메뉴 건너뛰기




Volumn 15, Issue 5, 2011, Pages

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modelling of subgroup analyses

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

EID: 79951562634     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta15050     Document Type: Review
Times cited : (78)

References (28)
  • 1
    • 64949096235 scopus 로고    scopus 로고
    • Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation
    • Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12(36).
    • (2008) Health Technol Assess , vol.12 , Issue.36
    • Wang, D.1    Cummins, C.2    Bayliss, S.3    Sandercock, J.4    Burls, A.5
  • 2
    • 12944252177 scopus 로고    scopus 로고
    • Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: A population-based retrospective study
    • Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatrics 2004;4(25):1-7.
    • (2004) BMC Pediatrics , vol.4 , Issue.25 , pp. 1-7
    • Fjaerli, H.O.1    Farstad, T.2    Bratlid, D.3
  • 3
    • 0842349460 scopus 로고    scopus 로고
    • Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease
    • Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004;23:S41-S45.
    • (2004) Pediatr Infect Dis J , vol.23
    • Cabalka, A.K.1
  • 4
    • 25844453682 scopus 로고    scopus 로고
    • British Medical Association and Royal Pharmaceutical Society of Great Britain, No. 59. London: BMA and RPS
    • British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. London: BMA and RPS; 2010.
    • (2010) British national formulary
  • 5
    • 4544286541 scopus 로고    scopus 로고
    • Anon, London: National Institute for Health and Clinical Excellence
    • Anon. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2009.
    • (2009) Guide to the methods of technology appraisal
  • 6
    • 33644888074 scopus 로고    scopus 로고
    • Hospitalization for respiratory syncytial virus infection in young children: Development of a clinical prediction rule
    • Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MW, de Groot R, Moll HA, et al. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J 2006;25(3):201-7.
    • (2006) Pediatr Infect Dis J , vol.25 , Issue.3 , pp. 201-207
    • Rietveld, E.1    Vergouwe, Y.2    Steyerberg, E.W.3    Huysman, M.W.4    de Groot, R.5    Moll, H.A.6
  • 7
    • 4944259712 scopus 로고    scopus 로고
    • Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease
    • Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89(10):961-5.
    • (2004) Arch Dis Child , vol.89 , Issue.10 , pp. 961-965
    • Duppenthaler, A.1    Ammann, R.A.2    Gorgievski-Hrisoho, M.3    Pfammatter, J.P.4    Aebi, C.5
  • 8
    • 34748906209 scopus 로고    scopus 로고
    • Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease
    • Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7(9):1471-80.
    • (2007) Expert Opin Biol Ther , vol.7 , Issue.9 , pp. 1471-1480
    • Feltes, T.F.1    Sondheimer, H.M.2
  • 10
    • 17944391919 scopus 로고    scopus 로고
    • Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group
    • Simoes EA, Sondheimer HM, Top FH, Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133(4):492-9.
    • (1998) J Pediatr , vol.133 , Issue.4 , pp. 492-499
    • Simoes, E.A.1    Sondheimer, H.M.2    Top Jr., F.H.3    Meissner, H.C.4    Welliver, R.C.5    Kramer, A.A.6
  • 11
    • 0033940772 scopus 로고    scopus 로고
    • Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study. IRIS Study Group
    • Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19(7):592-7.
    • (2000) Pediatr Infect Dis J , vol.19 , Issue.7 , pp. 592-597
    • Carbonell-Estrany, X.1    Quero, J.2    Bustos, G.3    Cotero, A.4    Domenech, E.5    Figueras-Aloy, J.6
  • 12
    • 0242298724 scopus 로고    scopus 로고
    • Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
    • Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-40.
    • (2003) J Pediatr , vol.143 , Issue.4 , pp. 532-540
    • Feltes, T.F.1    Cabalka, A.K.2    Meissner, H.C.3    Piazza, F.M.4    Carlin, D.A.5    Top Jr., F.H.6
  • 13
    • 0031683919 scopus 로고    scopus 로고
    • Palivisumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants
    • The IMpact-RSV Study Group
    • The IMpact-RSV Study Group. Palivisumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7.
    • (1998) Pediatrics , vol.102 , Issue.3 , pp. 531-537
  • 14
    • 0034821962 scopus 로고    scopus 로고
    • Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons
    • IRIS Study Group
    • Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20(9):874-9.
    • (2001) Pediatr Infect Dis J , vol.20 , Issue.9 , pp. 874-879
    • Carbonell-Estrany, X.1    Quero, J.2
  • 15
    • 0036269392 scopus 로고    scopus 로고
    • Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting
    • Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002;91(5):593-8.
    • (2002) Acta Paediatr , vol.91 , Issue.5 , pp. 593-598
    • Eriksson, M.1    Bennet, R.2    Rotzen-Ostlund, M.3    von Sydow, M.4    Wirgart, B.Z.5
  • 16
    • 6344280211 scopus 로고    scopus 로고
    • Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain
    • IRIS Study Group
    • Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23(9):815-20.
    • (2004) Pediatr Infect Dis J , vol.23 , Issue.9 , pp. 815-820
    • Figueras-Aloy, J.1    Carbonell-Estrany, X.2    Quero, J.3
  • 17
    • 58849101190 scopus 로고    scopus 로고
    • A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study
    • Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78.
    • (2008) Respir Res , vol.9 , pp. 78
    • Simoes, E.A.1    Carbonell-Estrany, X.2    Fullarton, J.R.3    Liese, J.G.4    Figueras-Aloy, J.5    Doering, G.6
  • 18
    • 53049109274 scopus 로고    scopus 로고
    • FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks
    • Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, Fernandez-Colomer B, Guzman-Cabanas J, Echaniz-Urcelay I, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27(9):788-93.
    • (2008) Pediatr Infect Dis J , vol.27 , Issue.9 , pp. 788-793
    • Figueras-Aloy, J.1    Carbonell-Estrany, X.2    Quero-Jimenez, J.3    Fernandez-Colomer, B.4    Guzman-Cabanas, J.5    Echaniz-Urcelay, I.6
  • 19
    • 47149094332 scopus 로고    scopus 로고
    • Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry
    • Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008;28(7):511-17.
    • (2008) J Perinatol , vol.28 , Issue.7 , pp. 511-517
    • Frogel, M.1    Nerwen, C.2    Cohen, A.3    van Veldhuisen, P.4    Harrington, M.5    Boron, M.6
  • 20
    • 52249108047 scopus 로고    scopus 로고
    • Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand
    • Grimwood K, Cohet C, Rich FJ, Cheng S, Wood C, Redshaw N, et al. Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand. Epidemiol Infect 2008;136(10):1333-41.
    • (2008) Epidemiol Infect , vol.136 , Issue.10 , pp. 1333-1341
    • Grimwood, K.1    Cohet, C.2    Rich, F.J.3    Cheng, S.4    Wood, C.5    Redshaw, N.6
  • 21
    • 6344278290 scopus 로고    scopus 로고
    • The Pediatric Investigators Collaborative Network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation
    • Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23(9):806-14.
    • (2004) Pediatr Infect Dis J , vol.23 , Issue.9 , pp. 806-814
    • Law, B.J.1    Langley, J.M.2    Allen, U.3    Paes, B.4    Lee, D.S.5    Mitchell, I.6
  • 22
    • 44049087819 scopus 로고    scopus 로고
    • Comment on the Austrian consensus paper on prophylaxis of RSV infection with palivizumab and post-RSV respiratory tract disease
    • Liese J. Comment on the Austrian consensus paper on prophylaxis of RSV infection with palivizumab and post-RSV respiratory tract disease. Monatsschrift fur Kinderheilkunde 2008;156(4):384.
    • (2008) Monatsschrift fur Kinderheilkunde , vol.156 , Issue.4 , pp. 384
    • Liese, J.1
  • 24
    • 34548677546 scopus 로고    scopus 로고
    • Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics
    • Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166(12):1267-72.
    • (2007) Eur J Pediatr , vol.166 , Issue.12 , pp. 1267-1272
    • Rossi, G.A.1    Medici, M.C.2    Arcangeletti, M.C.3    Lanari, M.4    Merolla, R.5    Paparatti, U.D.6
  • 25
    • 0037387758 scopus 로고    scopus 로고
    • Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany
    • Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162(4):230-6.
    • (2003) Eur J Pediatr , vol.162 , Issue.4 , pp. 230-236
    • Liese, J.G.1    Grill, E.2    Fischer, B.3    Roeckl-Wiedmann, I.4    Carr, D.5    Belohradsky, B.H.6
  • 26
    • 3042760382 scopus 로고    scopus 로고
    • Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection
    • Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89(7):673-8.
    • (2004) Arch Dis Child , vol.89 , Issue.7 , pp. 673-678
    • Greenough, A.1    Alexander, J.2    Burgess, S.3    Bytham, J.4    Chetcuti, P.A.5    Hagan, J.6
  • 27
    • 16644380035 scopus 로고    scopus 로고
    • Economic analysis of palivizumab in infants with congenital heart disease
    • Yount LE, Mahle WT, Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114(6):1606-11.
    • (2004) Pediatrics , vol.114 , Issue.6 , pp. 1606-1611
    • Yount, L.E.1    Mahle, W.T.2    Yount, L.E.3    Mahle, W.T.4
  • 28
    • 33846066254 scopus 로고    scopus 로고
    • Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis
    • Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. Pharmacoeconomics 2007;25(1):55-71.
    • (2007) Pharmacoeconomics , vol.25 , Issue.1 , pp. 55-71
    • Nuijten, M.J.C.1    Wittenberg, W.2    Lebmeier, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.